Yip AY - Search Results

1

Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer.

Han HS, Reis IM, Zhao W, Kuroi K, Toi M, Suzuki E, Syme R, Chow L, Yip AY, Glück S. Han HS, et al. Among authors: yip ay. Eur J Cancer. 2011 Nov;47(17):2537-45. doi: 10.1016/j.ejca.2011.06.027. Epub 2011 Jul 7. Eur J Cancer. 2011. PMID: 21741825

2

Clinical experience with docetaxel for Chinese breast cancer patients: hematological toxicity profiles.

Yip AY, Chow LW. Yip AY, et al. Breast Cancer. 2006;13(2):192-6. doi: 10.2325/jbcs.13.192. Breast Cancer. 2006. PMID: 16755116 Free article.

3

Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.

Chow LW, Tung SY, Ng TY, Im SA, Lee MH, Yip AY, Toi M, Glück S. Chow LW, et al. Among authors: yip ay. Expert Opin Investig Drugs. 2013 Mar;22(3):299-307. doi: 10.1517/13543784.2013.766715. Expert Opin Investig Drugs. 2013. PMID: 23394482 Clinical Trial.

4

Acceptable cardiac safety profile of neoadjuvant 5-fluorouracil, epirubicin, cyclophosphamide and celecoxib (FEC-C) for breast cancer: a subanalysis of biomarkers for cardiac injury.

Chow LW, Loo WT, Yip AY, Ng EL. Chow LW, et al. Among authors: yip ay. Int J Biol Markers. 2013 Apr 23;28(1):E92-9. doi: 10.5301/jbm.5000012. Int J Biol Markers. 2013. PMID: 23592005 Free article.

5

The future perspectives of breast cancer therapy.

Chow LW, Yiu CC, Yip AY, Loo WT. Chow LW, et al. Among authors: yip ay. Biomed Pharmacother. 2006 Jul;60(6):259-62. doi: 10.1016/j.biopha.2006.06.010. Epub 2006 Jun 23. Biomed Pharmacother. 2006. PMID: 16824726 Review.

6

Breast cancer management: the way forward.

Yip AY, Chow LW. Yip AY, et al. Hong Kong Med J. 2009 Aug;15(4):244-5. Hong Kong Med J. 2009. PMID: 19652228 Free article. No abstract available.

7

Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial.

Chow LW, Yip AY, Chu WP, Loo WT, Toi M. Chow LW, et al. Among authors: yip ay. J Steroid Biochem Mol Biol. 2011 May;125(1-2):112-9. doi: 10.1016/j.jsbmb.2010.12.018. Epub 2011 Jan 12. J Steroid Biochem Mol Biol. 2011. PMID: 21236344 Clinical Trial.

8

Prevention of oncological diseases: primary and secondary prevention.

Chow LW, Yip AY, Ng EL. Chow LW, et al. Among authors: yip ay. Int J Biol Markers. 2012 Dec 27;27(4):e337-43. doi: 10.5301/JBM.2012.10370. Int J Biol Markers. 2012. PMID: 23250774 Free article.

9

Relationship of CD44+CD24-/low breast cancer stem cells and axillary lymph node metastasis.

Wei W, Hu H, Tan H, Chow LW, Yip AY, Loo WT. Wei W, et al. Among authors: yip ay. J Transl Med. 2012 Sep 19;10 Suppl 1(Suppl 1):S6. doi: 10.1186/1479-5876-10-S1-S6. Epub 2012 Sep 19. J Transl Med. 2012. PMID: 23046710 Free PMC article.

10

Translational research to realize the full potential of novel agents--an opportunity for vinflunine?

Yip AY, Ong EY, Chow LW. Yip AY, et al. Expert Opin Drug Saf. 2012 May;11 Suppl 1:S5-8. doi: 10.1517/14740338.2011.624092. Epub 2011 Sep 30. Expert Opin Drug Saf. 2012. PMID: 21957991

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

34 results

Search Page

Filters